Combination therapy reverses hyperglycemia in NOD mice with established type 1 diabetes

Diabetes

Volumn 64, Issue 11, 2015, Pages 3873-3884

  Xue, Song ^a   Posgai, Amanda ^a   Wasserfall, Clive ^a   Myhr, Courtney ^a   Campbell Thompson, Martha ^a   Mathews, Clayton E ^a   Brusko, Todd ^a   Rabinovitch, Alex ^b   Savinov, Alexei ^b   Battaglia, Manuela ^c   Schatz, Desmond ^a   Haller, Michael ^a   Atkinson, Mark A ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; GRANULOCYTE COLONY STIMULATING FACTOR; PROTON PUMP INHIBITOR; THYMOCYTE ANTIBODY; C PEPTIDE; INSULIN; LYMPHOCYTE ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; EXPERIMENTAL MODEL; FEMALE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; MONOTHERAPY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REMISSION; ANIMAL; BLOOD; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; METABOLISM; NONOBESE DIABETIC MOUSE; PANCREAS; TREATMENT OUTCOME;

ANIMALS; ANTILYMPHOCYTE SERUM; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HYPERGLYCEMIA; INSULIN; MICE; MICE, INBRED NOD; PANCREAS; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 84958865564     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-0164     Document Type: Article

References (29)

1. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358:221-229
2. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005;23:447-485
3. Atkinson MA. Evaluating preclinical efficacy. Sci Transl Med 2011;3:96cm22
4. Herold KC, Bluestone JA. Type 1 diabetes immunotherapy: is the glass half empty or half full? Sci Transl Med 2011;3:95fs1
5. Parker MJ, Xue S, Alexander JJ, et al. Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice. Diabetes 2009;58:2277-2284
6. Huang Y, Parker M, Xia C, et al. Rabbit polyclonal mouse antithymocyte globulin administration alters dendritic cell profile and function in NOD mice to suppress diabetogenic responses. J Immunol 2009;182:4608-4615
7. Haller MJ, Gitelman SE, Gottlieb PA, et al. Anti-thymocyte globulin/G-CSF treatment preserves b cell function in patients with established type 1 diabetes. J Clin Invest 2015;125:448-455
8. Suarez-Pinzon WL, Cembrowski GS, Rabinovitch A. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice. Diabetologia 2009;52:1680-1682
9. Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006;55:1695-1704
10. Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocininduced diabetic rats. Diabetes 2003;52:741-750
11. Suarez-Pinzon WL, Power RF, Yan Y, Wasserfall C, Atkinson M, Rabinovitch A. Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 2008;57:3281-3288
12. Wang TC, Bonner-Weir S, Oates PS, et al. Pancreatic gastrin stimulates islet differentiation of transforming growth factor alpha-induced ductular precursor cells. J Clin Invest 1993;92:1349-1356
13. Rooman I, Lardon J, Bouwens L. Gastrin stimulates beta-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue. Diabetes 2002;51:686-690
14. Jang JY, Kim SW, Han JK, et al. Randomized prospective trial of the effect of induced hypergastrinemia on the prevention of pancreatic atrophy after pancreatoduodenectomy in humans. Ann Surg 2003;237:522-529
15. Staeva TP, Chatenoud L, Insel R, Atkinson MA. Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials. Diabetes 2013;62:9-17
16. Greenbaum CJ, Schatz DA, Haller MJ, Sanda S. Through the fog: recent clinical trials to preserve b-cell function in type 1 diabetes. Diabetes 2012;61:1323-1330
17. Chmelova H, Cohrs CM, Chouinard JA, et al. Distinct roles of b-cell mass and function during type 1 diabetes onset and remission. Diabetes 2015;64:2148-2160
18. Tonkin DR, He J, Barbour G, Haskins K. Regulatory T cells prevent transfer of type 1 diabetes in NOD mice only when their antigen is present in vivo. J Immunol 2008;181:4516-4522
19. Tonkin DR, Haskins K. Regulatory T cells enter the pancreas during suppression of type 1 diabetes and inhibit effector T cells and macrophages in a TGF-beta-dependent manner. Eur J Immunol 2009;39:1313-1322
20. Richer MJ, Lavallée DJ, Shanina I, Horwitz MS. Immunomodulation of antigen presenting cells promotes natural regulatory T cells that prevent autoimmune diabetes in NOD mice. PLoS One 2012;7:e31153
21. Godebu E, Summers-Torres D, Lin MM, Baaten BJ, Bradley LM. Polyclonal adaptive regulatory CD4 cells that can reverse type I diabetes become oligoclonal long-term protective memory cells. J Immunol 2008;181:1798-1805
22. Weber SE, Harbertson J, Godebu E, et al. Adaptive islet-specific regulatory CD4 T cells control autoimmune diabetes and mediate the disappearance of pathogenic Th1 cells in vivo. J Immunol 2006;176:4730-4739
23. Li CR, Baaten BJ, Bradley LM. Harnessing memory adaptive regulatory T cells to control autoimmunity in type 1 diabetes. J Mol Cell Biol 2012;4:38-47
24. Arif S, Leete P, Nguyen V, et al. Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes. Diabetes 2014;63:3835-3845
25. Pugliese A, Yang M, Kusmarteva I, et al. The Juvenile Diabetes Research Foundation Network for Pancreatic Organ Donors with Diabetes (nPOD) Program: goals, operational model and emerging findings. Pediatr Diabetes 2014;15:1-9
26. Voltarelli JC, Couri CE, Stracieri AB, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007;297:1568-1576
27. Couri CE, Oliveira MC, Stracieri AB, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009;301:1573-1579
28. Schatz D, Gale EA, Atkinson MA. Why can't we prevent type 1 diabetes?: maybe it's time to try a different combination. Diabetes Care 2003;26:3326-3328
29. Griffin KJ, Thompson PA, Gottschalk M, Kyllo JH, Rabinovitch A. Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D):12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 2014;2:710-718